Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 10/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4078873 | 0.90 | TSHR (0.42) | TSHRKDM4ERORCALDH1A1 | |
| SCHEMBL310746 | 0.83 | ERN1 (0.58) | ERN1TSHRRORCTYR | |
| SCHEMBL16910534 | 0.80 | ALDH1A1 (0.45) | ERN1TSHRKDM4EALDH1A1 | |
| SCHEMBL570511 | 0.78 | MAPT (0.46) | ALDH1A1 | |
| SCHEMBL570512 | 0.78 | MAPT (0.46) | ALDH1A1 | |
| SCHEMBL570725 | 0.77 | MAPT (0.48) | KDM4EALDH1A1 | |
| SCHEMBL571064 | 0.77 | MAPT (0.48) | KDM4EALDH1A1 | |
| SCHEMBL15166639 | 0.76 | MAOB (0.48) | — | |
| SCHEMBL15166640 | 0.76 | MAOB (0.48) | — | |
| SCHEMBL7245766 | 0.76 | ALDH1A1 (0.56) | TSHRKDM4ERORCALDH1A1TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815940-B2 | Coumarin-chalcones as anticancer agents | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-08-26 | — | — | US | disclosed |
| US-20130210909-A1 | COUMARIN-CHALCONES AS ANTICANCER AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-08-15 | — | — | US | disclosed |
| EP-2601183-A1 | COUMARIN-CHALCONES AS ANTICANCER AGENTS | Council Of Scientific & Industrial Research (IN) | 2013-06-12 | — | — | EP | disclosed |
| WO-2012017454-A1 | COUMARIN-CHALCONES AS ANTICANCER AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210909-A1 | COUMARIN-CHALCONES AS ANTICANCER AGENTS | HCCS, XPO5, CIAPIN1 | ERN1 1438/4885TSHR 4656/4885KDM4E 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.